FDA grants regulatory approval of melphalan flufenamide in combination with dexamethasone for treatment of refractory multiple myeloma

Approval of this first in class peptide-drug conjugate that targets aminopeptidases was based on the HORIZON study which reported an overall response rate of 23.7% & median duration of response of 4.2 months in 97 patients who had received at least 4 prior lines of treatment.

Biospace Inc.